Got you covered.

CMS now covers next generation sequencing (NGS) for all cancer patients with refractory, relapsed or upfront stage III-IV disease. This is nice to know considering less than half of breast cancer patients eligible per previous guidelines received genetic testing in this analysis of 2013-2015 SEER data. This is expensive to know considering less than 9% of these select high-risk breast cancer patients were discovered to have pathogenic mutations (read: far less than 9% had changes in management). | Katz, J Clin Oncol 2018